Trial Profile
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpower010
- Sponsors Chugai Pharmaceutical; Roche
- 24 Oct 2023 Results of exploratory analyses to identify predictive biomarkers for atezolizumab outcomes using IMpower010 RNA sequencing (RNAseq) data, presented at the 48th European Society for Medical Oncology Congress.
- 12 Sep 2023 Results of exploratory analysis (n=549) assessing Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC presented at the 24th World Conference on Lung Cancer
- 31 Aug 2023 Results exploring the safety and tolerability of adjuvant atezolizumab by surgery type, published in the Journal of Thoracic and Cardiovascular Surgery